ArticleBMC neurology2022
Cranial autonomic symptoms in migraine are related to central sensitization: a prospective study of 164 migraine patients at a tertiary headache center.
Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Clinical Outcomes of Ultrasound-Guided Stellate Ganglion Block in Highly Treatment-Resistant Chronic Migraine: A 6-Month Prospective Single-Group Interventional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Cluster Analysis of Migraine-Associated Symptoms (CAMS) across the lifespan: a cross-sectional study.BMC neurology · 2026Article
- Interictal thermal pain hypersensitivity and central sensitization in migraine patients: a case-control study using quantitative sensory testing.Head & face medicine · 2026Article
- Expanding the Spectrum of Central Sensitivity Syndrome: Integrating Otologic Migraine as Otologic Central Sensitivity Syndrome.Brain sciences · 2026Review
- Investigation of Sensory and Neuropsychological Parameters in Migraine Sufferers: A Cross-Sectional Study with Negative Findings.Neurology and therapy · 2025Article
- Efficacy of galcanezumab in migraine central sensitizationScientific reports · 2024Article
- Cranial Autonomic Symptoms in Migraine Patient Presenting in the Department of Neurology of a Tertiary Care Center: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2024Article
- Cranial Autonomic Symptoms and Neck Pain in Differential Diagnosis of Migraine.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Autonomic symptoms in migraine: Results of a prospective longitudinal study.Frontiers in neurology · 2022Article
- Central Sensitization in Migraine: A Narrative Review.Journal of pain research · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCranial autonomic symptoms (CASs) during migraine attacks are reported to be quite common regardless of ethnicity. In our previous study investigating 373 migraineurs, we found that 42.4% of them had CASs. The patients with CASs more frequently had cutaneous allodynia than did those without CASs, and we speculated that CASs were associated with central sensitization. The present study searched for substantial evidence on the relationship between CASs and central sensitization in migraine patients.
methodsThis was a prospective cross-sectional study. We studied a new independent cohort of 164 migraineurs who presented to the Tominaga Hospital Headache Center from July 2018 until December 2019. The clinical features of CASs according to the criteria in ICHD-3 (beta) were investigated. We also evaluated central sensitization based on the 25 health-related symptoms utilizing the validated central sensitization inventory (CSI), and each symptom was rated from 0 to 4 resulting a total score of 0-100.
resultsThe mean age was 41.8 (range: 20 to 77) years old. One hundred and thirty-one patients (78.9%) were women. Eighty-six of the 164 (52.4%) patients had at least 1 cranial autonomic symptom. The CSI score of the patients with ≥3 CASs reflected a moderate severity and was significantly higher than in those without CASs (41.9 vs. 30.7, p = 0.0005). The score of the patients with ≥1 conspicuous CAS also reflected a moderate severity and was significantly higher than in those without CASs (40.7 vs. 33.2, p = 0.013). The patients in the CSI ≥40 group had lacrimation, aural fullness, nasal blockage, and rhinorrhea, which are cranial autonomic parasympathetic symptoms, significantly more frequently than those in the CSI < 40 group.
conclusionsMigraine patients with CASs showed significantly greater central sensitization than those without such symptoms. In particular, cranial parasympathetic symptoms were more frequent in centrally sensitized patients than in nonsensitized patients, suggesting that cranial parasympathetic activation may contribute to the maintenance of central sensitization.
trial registrationThis study was retrospectively registered with UMIN-CTR on 29 Aug 2020 ( UMIN000041603 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.